ArticleJournal of hepatocellular carcinoma2026
DEB-TACE Combined with Immunotherapy and Targeted Therapy for Advanced Hepatocellular Carcinoma with Scapular Metastasis: A Case Report.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced hepatocellular carcinoma (HCC) with massive intrahepatic tumors and bone metastases is associated with poor prognosis, and standard treatment options are limited. Bone metastases, particularly to rare sites such as the scapula, pose additional therapeutic challenges. Case Presentation: We report a patient with a giant intrahepatic HCC and scapular metastasis. The patient received three sessions of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with systemic therapy using lenvatinib and camrelizumab. Marked radiological regression and improvement in tumor markers were observed. The patient remained progression-free at the last documented follow-up of 16 months. Conclusion: The combination of DEB-TACE, lenvatinib, and camrelizumab for treating advanced hepatocellular carcinoma with scapular metastasis was shown to be feasible in this case and was associated with sustained disease control of both intrahepatic and extrahepatic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.